Damian Walker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9368366/publications.pdf

Version: 2024-02-01

38	1,537 citations	19 h-index	35 g-index
papers	citations	II-IIIQEX	g-mdex
39 all docs	39 docs citations	39 times ranked	2303 citing authors

#	Article	IF	CITATIONS
1	The Expanding Epidemics of HIV Type 1 Among Men Who Have Sex With Men in Low- and Middle-Income Countries: Diversity and Consistency. Epidemiologic Reviews, 2010, 32, 137-151.	3.5	180
2	Cost-effectiveness of water quality interventions for preventing diarrhoeal disease in developing countries. Journal of Water and Health, 2007, 5, 599-608.	2.6	135
3	Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001–2020. Bulletin of the World Health Organization, 2017, 95, 629-638.	3.3	109
4	Allowing for differential timing in cost analyses: discounting and annualization. Health Policy and Planning, 2002, 17, 112-118.	2.7	97
5	Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Economics (United Kingdom), 2000, 9, 681-698.	1.7	93
6	Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccineant. Vaccine, 2011, 29, 2371-2380.	3.8	93
7	Cost and unit cost calculations using step-down accounting. Health Policy and Planning, 2004, 19, 127-135.	2.7	91
8	Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base?. Health Policy and Planning, 2003, 18, 4-17.	2.7	74
9	Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods. Health Economics (United Kingdom), 2002, 11, 735-739.	1.7	64
10	Cost and cost-effectiveness guidelines: which ones to use?. Health Policy and Planning, 2001, 16, 113-121.	2.7	60
11	Reassessing the value of vaccines. The Lancet Global Health, 2014, 2, e251-e252.	6.3	49
12	Estimates of Health Care System Costs of Unsafe Abortion in Africa and Latin America. International Perspectives on Sexual and Reproductive Health, 2009, 35, 114-121.	3.7	44
13	Economic evaluation of parasitic diseases: A critique of the internal and external validity of published studies. Tropical Medicine and International Health, 2000, 5, 237-249.	2.3	39
14	The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. Addiction, 2004, 99, 1565-1576.	3.3	32
15	Foreword: Health Economic Evaluations in Low―and Middleâ€income Countries: Methodological Issues and Challenges for Priority Setting. Health Economics (United Kingdom), 2016, 25, 1-5.	1.7	31
16	Economic evaluations of non-communicable disease interventions in developing countries: a critical review of the evidence base. Cost Effectiveness and Resource Allocation, 2006, 4, 7.	1.5	30
17	Adherence to the iDSI reference case among published cost-per-DALY averted studies. PLoS ONE, 2019, 14, e0205633.	2.5	27
18	Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines. Pediatric Infectious Disease Journal, 2004, 23, 32-37.	2.0	22

#	Article	IF	CITATIONS
19	Economics methods in Cochrane systematic reviews of health promotion and public health related interventions. BMC Medical Research Methodology, 2006, 6, 55.	3.1	22
20	The effect of costs on Kenyan households' demand for medical care: why time and distance matter. Health Policy and Planning, 2017, 32, 1397-1406.	2.7	20
21	Cost–effectiveness of rotavirus vaccines. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 593-601.	1.4	19
22	The Highest Attainable Standard of Evidence (HASTE) for HIV/AIDS Interventions: Toward a Public Health Approach to Defining Evidence. Public Health Reports, 2012, 127, 572-584.	2.5	19
23	The cost effectiveness of universal antenatal screening for HIV in New Zealand. Aids, 2003, 17, 741-748.	2.2	18
24	A factorial-design cluster randomised controlled trial investigating the cost-effectiveness of a nutrition supplement and an exercise programme on pneumonia incidence, walking capacity and body mass index in older people living in Santiago, Chile: the CENEX study protocol. Nutrition Journal, 2007, 6, 14.	3.4	18
25	Adolescent vaccination in the developing world: time for serious consideration?. Vaccine, 2004, 22, 781-785.	3.8	15
26	Evidenced-based decision making about Hib vaccination. Lancet, The, 2005, 365, 936-937.	13.7	12
27	Evidence base for interventions in complex emergencies. Lancet, The, 2005, 365, 842-843.	13.7	10
28	The economics of TB control in developing countries. Expert Opinion on Pharmacotherapy, 2003, 4, 359-368.	1.8	9
29	ARE VACCINATION SITES IN BANGLADESH SCALE EFFICIENT?. International Journal of Technology Assessment in Health Care, 2003, 19, 692-697.	0.5	8
30	Household Costs of Diarrhea by Etiology in 7 Countries, The Global Enterics Mulitcenter Study (GEMS). Open Forum Infectious Diseases, 2019, 6, ofz150.	0.9	8
31	Antibiotic treatment for newborns with congenital syphilis. The Cochrane Library, 2019, 2019, CD012071.	2.8	8
32	Surviving the Impact of HIV-Related Illness in the Zambian Business Sector. AIDS Patient Care and STDs, 2003, 17, 353-363.	2.5	7
33	Syphilis: A Forgotten Priority. PLoS Medicine, 2006, 3, e204.	8.4	6
34	Malaria prevention measures in Burkina Faso: distribution and households expenditures. International Journal for Equity in Health, 2014, 13, 108.	3.5	6
35	An economic analysis of midwifery training programmes in South Kalimantan, Indonesia. Bulletin of the World Health Organization, 2002, 80, 47-55.	3.3	5
36	Cost-effectiveness analysis and priority-setting: global approach without local meaning?. , 2001, , 140-156.		2

#	Article	IF	CITATIONS
37	Antibiotics for congenital syphilis. The Cochrane Library, 0, , .	2.8	1
38	Cost-Effectivess in Low- and Middle-Income Countries: A Review of the Debates Surrounding Decision Rules. SSRN Electronic Journal, 0, , .	0.4	0